Lipids & metabolic liver disease
Modification of the all-cause and cardiovascular disease related mortality risk with changes in the metabolic syndrome status: a population-based prospective cohort study in Taiwan
Authors' conclusion
Recovery from MetS was significantly associated with a lower risk of all-cause and CVD mortality, whereas development of MetS was associated with increased risk.
Study context
- Population
- Adults in the Taiwan MJ Health Management Institution health surveillance program (1998–2016) with ≥2 repeated metabolic syndrome (MetS) measures 5.9 (4.6) years apart
- Participants
- 236,216 adults4,436,842 person-years
- Exposure
- Change in MetS status over time
- MetS-freen = 173,116
- MetS-developedn = 22,607
- MetS-recoveredn = 13,616
- MetS-persistentn = 26,877reference
- Outcome
- All-cause and CVD mortality
- Follow-up
- 18.8 (5.2) years
Methodological detailsmultivariable Cox proportional hazards model
- Multivariable Cox proportional hazards model
Main finding
As reported in the abstract
Adjusted hazard ratio (95% CI)
MetS-recoveredvs MetS-persistentall-cause mortality
0.87(0.82–0.92)
MetS-recoveredvs MetS-persistentCVD mortality
0.81(0.71–0.93)
MetS-developedvs MetS-freeall-cause mortality
1.11(1.05–1.17)
MetS-developedvs MetS-freeCVD mortality
1.22(1.07–1.39)
- Deaths during follow-up
- 14,226
- CVD-related deaths
- 2671 (19%)
Observational data: associations, not effects.
Further findings
Crude CVD mortality rate per 1000 person-years — between MetS-free and MetS-developed · across the four groups
P < 0.001
Original publication
Modification of the all-cause and cardiovascular disease related mortality risk with changes in the metabolic syndrome status: a population-based prospective cohort study in Taiwan. Diabetes Metab. Published 20 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →